연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
2201. The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Heo JY1,2, Park C1, Keam B1,3, Ock CY1, Kim M1, Kim TM1,3, Kim DW1,3, Kim SH4, Kim YJ4, Lee JS4, Heo DS1,3.
Thorac Cancer. 2019 Nov;10(11):2117-2123. doi: 10.1111/1759-7714.13195. Epub 2019 Sep 11.
Link
2200. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ1, Keam B2, Ock CY3, Song S4, Kim M3, Kim SH1, Kim KH5, Kim JS5, Kim TM6, Kim DW6, Lee JS1, Heo DS6.
Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.
Link
2199. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Kim R1, Keam B2, Hahn S3, Ock CY1, Kim M1, Kim TM4, Kim DW4, Heo DS4.
Clin Lung Cancer. 2019 Sep;20(5):331-338.e4. doi: 10.1016/j.cllc.2019.05.009. Epub 2019 May 11.
Link
2198. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Yoo SH1, Keam B2,3, Ock CY1, Kim S4, Han B5, Kim JW6, Lee KW6, Jeon YK4, Jung KC4, Chung EJ7, Kwon SK7, Ahn SH7, Sung MW7, Heo DS1,8.
Sci Rep. 2019 May 22;9(1):7680. doi: 10.1038/s41598-019-44206-2.
Link
2197. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
Choi M1, Keam B2, Ock CY3, Kim M3, Kim TM3, Kim DW3, Heo DS3.
Clin Lung Cancer. 2019 Jul;20(4):e442-e451. doi: 10.1016/j.cllc.2019.03.005. Epub 2019 Mar 29.
Link
2196. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R1, Keam B2,3, Kim S4, Kim M1, Kim SH5, Kim JW6, Kim YJ5, Kim TM1,7, Jeon YK7,4, Kim DW1,7, Chung DH7,4, Lee JS5, Heo DS1,7.
BMC Cancer. 2019 Jan 7;19(1):19. doi: 10.1186/s12885-018-5214-8.
Link
2195. Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.
Keam B1,2, Kang CK1, Jun KI1, Moon SM3, Suh KJ3, Lee DW1,2, Ock CY1,2, Kim M1,2, Choi Y4, Lim Y1,2, Lee KH1,2, Kim SH3, Kim TM1,2, Kim TY1,2, Oh DY1,2, Kim DW1,2, Im SA1,2, Lee JS3, Kim ES3, Kim HB3, Kim NJ1, Kim YJ3, Park WB1, Oh MD1.
Clin Infect Dis. 2019 Nov 4. pii: ciz1092. doi: 10.1093/cid/ciz1092. [Epub ahead of print]
Link
2194. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ1, Kim S1, Kim DW1,2,3, Kim M1,2, Keam B1,2, Kim TM1,2, Lee Y1, Koh J4, Jeon YK4,5, Heo DS1,2,3
Cancer Res Treat. 2019 Jul;51(3):1231-1240. doi: 10.4143/crt.2018.486. Epub 2018 Dec 31.
Link
2193. Interstitial Lung Abnormalities: Poor Prognosis for Patients with Lung Cancer
Goo JM
Radiology. 2019 Aug;292(2):499-500
Link
2192. Effect of Reconstruction Parameters on the Quantitative Analysis of Chest Computed Tomography
Kim H, Goo JM, Ohno Y, Kauczor HU, Hoffman EA, Gee JC, van Beek EJR.
J Thorac Imaging. 2019 Mar;34(2):92-102.
Link